Ige A

Bittensor Revenue Search 35 – Discovering talent & potential in AI start-ups – SN10 Swap

The Bittensor Revenue Search show, hosted by Mark Creaser and Siam Kidd, returned for another highly anticipated episode 35 featuring Sam, the founder of Subnet 10 — one of Bittensor’s most practical and fast-growing subnets. While the episode began with news around subnet acquisitions and transparency in the Bittensor community, it quickly turned into a…

Read More

TAO (Bittensor) vs RENDER

SUMMARY: The video compares Bittensor ($TAO) and Render ($RNDR), two leading AI-focused crypto projects, analyzing their use cases, teams, and tokenomics. While Render enables decentralized GPU rendering for creators, Bittensor rewards contributors who provide intelligence to its decentralized AI network. The host concludes that $TAO outperforms $RNDR in utility, decentralization, and long-term potential — predicting…

Read More

$TAO Halving Shockwave — Will Bittensor’s Economy Survive It?

When Bittensor launched dTAO in February 2025, it introduced one of the most significant tokenomic changes in the network’s history. Alongside Bittensor’s native token, $TAO, each subnet now has its own $ALPHA (subnet token) — effectively creating a dual-emission economy within the Bittensor ecosystem. This system was designed to reward subnet participants while maintaining liquidity….

Read More

How xTAO is Balancing Volatility and Sustainable Yield

SUMMARY: The video explores xTAO’s approach to cryptocurrency treasury management, detailing how it balances volatility, operational efficiency, and tax advantages through its TSXV listing and Cayman Islands base.  It highlights xTAO’s transparent capital structure, staking-based cash flow model, and strategic use of custodians. The discussion also compares xTAO’s strategy to Michael Saylor’s accretive dilution, emphasizing…

Read More

Exploring the Future of Drug Discovery on Bittensor

Bringing a new drug to market is notoriously slow and expensive. Recent analyses estimate that the median cost — including failures — sits around $985 million, while the average exceeds $1.3 billion per approved drug. Even during the COVID-19 pandemic, governments spent tens of billions of dollars on vaccine development, revealing how resource-intensive and centralized…

Read More

How Swarm Plans To Make Money

We read Swarm’s Substack article on how their subnet plans to generate revenue — and a few things really stood out. First, their subnet isn’t just running drone simulations for fun. It’s been a live testing ground for developing autonomous models capable of piloting a real quadrotor drone — equipped with LiDAR and precise sensors….

Read More